Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Evaluatie van de Clinical Frailty Scale (CFS) als risicofactor voor mortaliteit bij volwassen patiënten ≤65 jaar die zijn opgenomen op de intensive care voor septische shock. (Woodstock)

24 september 2026 bijgewerkt door: Centre Hospitalier de Lens

The aim of the study is to demonstrate that "frail" patients, defined as having a CFS score greater than or equal to 5, and "severely" frail patients, defined as having a CFS score between [6-7] as defined by Bagshaw et al (14), constitute an independent risk factor (RF) for mortality.

In the same way, as an exploratory study, we will try to find out whether clinical frailty constitutes a risk factor for extending the length of hospital stay, the risk of short/medium-term readmission, as has already been demonstrated for patients admitted to intensive care from all causes (15), or for impaired quality of life.

The objective is to have a better understanding of the implications and outcomes associated with pre-hospital frailty in young critically ill patients.

This analysis will also help to clarify prognoses and contribute to better decision-making on the intensity and proportionality of care, as well as providing better information and helping to manage the expectations of patients and their families in terms of survival prognosis and subsequent quality of life.

Studie Overzicht

Toestand

Werving

Conditie

Gedetailleerde beschrijving

Recent studies show the impact of frailty in a middle-aged or even young population of patients admitted to critical care in terms of mortality (13), and the persistent risk of impairment of physical and mental capacities after resuscitation (14). To date, few studies have looked at clinical frailty as a risk factor for mortality in a middle-aged or young population, more specifically those suffering from septic shock, which is already known to be a major factor in morbidity and mortality (15,16), with repercussions on long-term quality of life.

The aim of the study is to demonstrate that "frail" patients, defined as having a CFS score greater than or equal to 5, and "severely" frail patients, defined as having a CFS score between [6-7] as defined by Bagshaw et al (14), constitute an independent risk factor (RF) for mortality.

In the same way, as an exploratory study, we will try to find out whether clinical frailty constitutes a risk factor for extending the length of hospital stay, the risk of short/medium-term readmission, as has already been demonstrated for patients admitted to intensive care from all causes (15), or for impaired quality of life.

The objective is to have a better understanding of the implications and outcomes associated with pre-hospital frailty in young critically ill patients.

This analysis will also help to clarify prognoses and contribute to better decision-making on the intensity and proportionality of care, as well as providing better information and helping to manage the expectations of patients and their families in terms of survival prognosis and subsequent quality of life.

Studietype

Observationeel

Inschrijving (Geschat)

200

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

  • Frankrijk
      • Boulogne-sur-Mer, Frankrijk, 62321
        • Werving
        • CH Boulogne sur Mer
        • Hoofdonderzoeker:
          • Charles DETOLLENAERE, Dr
      • Béthune, Frankrijk, 62408
        • Werving
        • Ch Germon Et Gauthier
        • Hoofdonderzoeker:
          • Ghada SBOUI, Dr
      • Dijon, Frankrijk, 21079
        • Werving
        • CHU de Dijon
        • Hoofdonderzoeker:
          • Jean-Pierre QUENOT, Pr
      • Lens, Frankrijk
        • Werving
        • CH de Lens
        • Hoofdonderzoeker:
          • Guillaume DEGOUY, Doctor
      • Lille, Frankrijk, 59037
        • Werving
        • CHU Lille
        • Hoofdonderzoeker:
          • Alexandre GAUDET, Dr

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

All patients admitted to intensive care will be studied for this study. Patients meeting the inclusion criteria and with no non-inclusion criteria will be included in the study after obtaining the patient's or relative's, if applicable, non-objection.

Beschrijving

Inclusion Criteria:

  • Patients aged ≥18 years and ≤ 65 years
  • Patient admitted to intensive care - resuscitation
  • Patient admitted for suspected or documented type 3 sepsis
  • Presence of vasopressor amines to maintain MAP > 65mmHg despite filling
  • Lactatemia ≥ 2 mmol/L on admission.

Exclusion Criteria:

  • Patient moribund on admission
  • Patients with severe pre-existing dementia and/or cognitive decline, suffering from severe neurodegenerative diseases that prevent the patient from living independently at baseline, including mental illness requiring institutionalisation, including acquired or congenital mental retardation, etc.
  • Pregnant women or women in labour
  • Patients under guardianship or curatorship
  • Patients deprived of their liberty
  • Patient and/or family unable to speak or understand French.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: OTHER
  • Tijdsperspectieven: PROSPECTIVE

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To show that the frailty score on admission is a risk factor for mortality at D28, independent of known risk factors, in young patients admitted to intensive care (ICU) for sepsis or septic shock.
Tijdsspanne: 28 days after inclusion

The odds ratio of frail patients to non-frail patients for the risk of all-cause death at D28
28 days after inclusion

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To study the association, independently of known risk factors, between the frailty score on admission and mortality at day 90.
Tijdsspanne: 90 days after inclusion

Time from admission to death or last news, censored at D90
90 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and length of hospital stay
Tijdsspanne: 90 days after inclusion

The time between admission to IS and live discharge from hospital, death is considered a concurrent risk, the data are censored at 90 days
90 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and the number of days with recourse to invasive therapies
Tijdsspanne: 90 days after inclusion

Number of days with mechanical ventilation, with amines, with recourse to extra-renal purification (EER) during the IS stay.
90 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and readmission to critical care or hospitalisation before D90, among patients discharged alive from ICU before D90.
Tijdsspanne: 90 days after inclusion

Readmission to critical care or hospitalisation before D90, among patients discharged alive from ICU before D90.
90 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and describe changes in frailty between ICU admission and D90 in patients alive at D90.
Tijdsspanne: 90 days after inclusion

Change in frailty score defined by the CFS (continuous) between admission and D90 (in hospital or at home).
90 days after inclusion
To study the association, independently of known risk factors, between the frailty score on admission and describe quality of life at D90 in patients alive at D90.
Tijdsspanne: 90 days after inclusion

Quality of life measured by the EQ5D score at D90 (in hospital or at home).
90 days after inclusion

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Centre Hospitalier de Lens

Medewerkers

University Hospital, Lille

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

21 augustus 2023

Primaire voltooiing (Geschat)

18 september 2027

Studie voltooiing (Geschat)

1 november 2027

Studieregistratiedata

Eerst ingediend

26 juni 2023

Eerst ingediend dat voldeed aan de QC-criteria

26 juni 2023

Eerst geplaatst (Werkelijk)

3 juli 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

28 september 2026

Laatste update ingediend die voldeed aan QC-criteria

24 september 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 2023-02

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren